Anlong

ANLONG was founded in August 2019 as a startup company focused on gene therapy. Its business areas cover gene therapy for wet age-related macular degeneration (wAMD) in ophthalmology, AAV vector screening, and more. These are currently among the most effective fields in gene therapy, characterized by broad market prospects, strong business scalability, and high added value. Additionally, ANLONG is also collaborating with leading foreign companies to initiate gene therapy projects for rare diseases.